Name: Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening (Video) | JoVE Journal
Uploaded: 2025-09-05T13:40:00.000+00:00
Duration: 6 min 50 s
Description: Learn metabolic profiling of 3D glioma spheroids using Seahorse technology for drug screening. This method reveals tumor energy metabolism and resistance mechanisms to improve cancer therapy evaluation.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This research was funded by the National Natural Science Foundation of China, grant numbers 82471329 and 82001248.

NOTE: The complete specifications of all reagents and consumables are detailed in the Table of Materials.
1. 2D cell culture
<ol>
	<li>Maintain U87 cells in minimum essential medium (MEM) supplemented with 10% (v/v) fetal bovine serum (FBS) under sterile conditions. Perform standard passaging procedures once the cells reach 80% confluence. 
	NOTE: Throughout the culture process, closely monitor the cell status and exclude cells exhibiting abnormal growth or morphological changes from subsequent experiments.</li>
	<li>Seed U87 cells into 10 cm cell culture dishes and incubate in a sterile cell culture incubator at 37 &#176;C with 5% (v/v) CO2 and 90-95% relative humidity. 
	NOTE: The medium should be replaced regularly to maintain optimal growth conditions.</li>
</ol>
2. 3D cell spheroid formation
<ol>
	<li>Experimental preparation
	<ol>
		<li>Review the entire workflow in Figure 1 before commencing experimental procedures. 
		CAUTION: Strictly adhere to aseptic techniques throughout the experiment to ensure cell health and prevent contamination.</li>
	</ol>
	</li>
	<li>Cell dissociation and counting
	<ol>
		<li>Remove the spent medium from the cell culture dish and wash the U87 cells three times with 9 mL of phosphate-buffered saline (PBS) (3 mL per wash). Dispose of used reagents in a 20-25% (v/v) bleach solution to inactivate all bioactive materials.</li>
		<li>Add 1 mL of trypsin solution to the dish and incubate at 37 &#176;C for 2-3 min. Neutralize trypsin with 2 mL of DMEM containing 10% FBS preheated to 37 &#176;C once all the cells are detached under microscopic observation.</li>
		<li>Transfer the cell suspension to a 15 mL centrifuge tube and centrifuge at 200 &#215; g for 3 min. Discard the supernatant, and resuspend the cell pellet in 1 mL of DMEM supplemented with 10% FBS. Pipette the cells gently to ensure a uniform cell suspension. Then count via a hemocytometer or automated cell counter, and record the initial cell count. 
		NOTE: Handle the cells gently during washing and media addition to avoid mechanical damage. The pipetting force can be controlled to prevent bubble formation, which can affect cell viability and counting accuracy.</li>
	</ol>
	</li>
	<li>Cell suspension dilution
	<ol>
		<li>Preheat the unused medium to 37 &#176;C. Maintain the cell suspensions at room temperature (RT; 25 &#177; 2 &#176;C) for 30 min.</li>
		<li>On the basis of the initial cell count, dilute the cell suspension with DMEM containing 10% FBS to a final volume of 20 mL, ensuring approximately 200,000 cells. 
		NOTE: Prior to final dilution, gently pipette the cell suspension to prevent sedimentation. The unused medium was maintained at 37 &#176;C, and the cell suspensions were incubated at RT. If 96 wells with 1,500 cells per well were seeded, a total volume of 22 mL was prepared to account for excess. The diluted cell suspension was transferred to a 50 mL sterile centrifuge tube and mixed thoroughly.</li>
	</ol>
	</li>
	<li>Cell seeding in ultra-low attachment 96-well plates
	<ol>
		<li>Mix the final cell suspension thoroughly via a 200 &#181;L pipette. Add 200 &#181;L of the suspension (1,500 cells/well) slowly to each well of a transparent round-bottom ultra-low attachment 96-well plate along the edge. 
		NOTE: For efficiency, consider the use of a multichannel pipette.</li>
		<li>Discard any remaining suspension after all the wells are filled to prevent contamination.</li>
	</ol>
	</li>
	<li>Centrifugation
	<ol>
		<li>Seal the plate tightly with parafilm to prevent leakage during centrifugation. Centrifuge the mixture at 200 &#215; g for 2 min to pellet the cells at the bottom of each well.</li>
		<li>Remove the plate from the centrifuge, carefully remove the parafilm, and place the plate in a 37 &#176;C, 5% CO2 incubator.</li>
	</ol>
	</li>
</ol>
3. Poly-D-Lysine coating of the metabolic assay plates
NOTE: Metabolic assay microplate is a specialized microplate designed for cell spheroid adhesion during extracellular flux analysis.
<ol>
	<li>Prepare a coating solution by dissolving 5 mg of poly-D-lysine in 50 mL of sterile water. Mix thoroughly.</li>
	<li>Add 30 &#181;L of the coating solution to each well of the metabolic assay plate. Ensure the absence of bubbles by gently shaking or aspirating the excess solution.</li>
	<li>Incubate the plate and cover it for 20 min at RT. Aspirate the coating solution, and wash the wells twice with 200 &#181;L of sterile water.</li>
	<li>Air dry the plate for at least 30 min and then heat at 37 &#176;C without CO2 for 30 min to stabilize the coating.</li>
	<li>Add 175 &#181;L of preheated medium to each well, and keep the plate at 37 &#176;C in a CO2-free incubator until it is ready for cell spheroid transfer.</li>
</ol>
4. Monitoring spheroid growth
<ol>
	<li>Transfer the spheroid plates to a high-content imaging system after 5 days of culture.</li>
	<li>Configuration imaging parameters: Set the temperature to 37 &#176;C and the CO2 to 5%, and adjust the plate type, channels, and focus range.</li>
	<li>Acquire spheroid images via a confocal microscope with 10x objectives and an imaging software.</li>
	<li>Identify wells containing intact spheroids (e.g., Figure 2A-C) and record their positions for transfer. Exclude wells with irregular spheroids (e.g., Figure 2D).&#34;</li>
</ol>
5. Spheroid treatment
NOTE: Drug treatment was performed on mature 3D spheroids to assess metabolic responses.
<ol>
	<li>Spheroid group assignment
	<ol>
		<li>Assign intact spheroids to two groups: 
		Control group: 6 replicate wells 
		Treatment group: 6 replicate wells (fenofibrate-treated)</li>
	</ol>
	</li>
	<li>Drug solution preparation
	<ol>
		<li>Prepare the fenofibrate working solution in fresh pre-warmed medium at the optimal concentration (e.g., 100 &#181;M). 
		NOTE:Treatment groups were reconstituted in 100% DMSO to create stock solutions, which were subsequently diluted in fresh pre-warmed medium. The control groups were administered the same final concentration of DMSO (0.1% v/v) as was present in the drug-treated samples. The final concentration was determined via dose-response assays.</li>
	</ol>
	</li>
	<li>Medium replacement
	<ol>
		<li>Aspirate 100 &#181;L of medium from each well slowly along the wall. 
		NOTE: Avoid contacting the well bottom to prevent spheroid disturbance.</li>
		<li>Add 100 &#181;L of fresh medium to the control wells.</li>
		<li>Add 100 &#181;L of fenofibrate working solution to the treatment wells.</li>
	</ol>
	</li>
	<li>Posttreatment incubation
	<ol>
		<li>Return the plate gently to 37 &#176;C in a 5% CO2 incubator. Culture for 72 h.</li>
	</ol>
	</li>
	<li>Morphological assessment
	<ol>
		<li>Assess the integrity of the spheroids following the imaging procedure in step 4.</li>
	</ol>
	</li>
</ol>
6. Transfer of cell spheroids
<ol>
	<li>Carefully remove the spheroid-containing low-attachment plate from the imaging system and place it on a sterile surface within a biosafety cabinet. Place the poly-L-lysine-coated assay plate adjacent to each other for transfer.</li>
	<li>Trim the tip of a 20 &#181;L pipette to facilitate gentle aspiration of the cell spheroids without damage.</li>
	<li>Gently aspirate each intact spheroid from the bottom of the well and transfer it to the corresponding well of the cell plate, allowing it to settle for 20 s. Confirm adhesion by the absence of floating fragments under 10&#215; microscopy.</li>
	<li>Repeat for all spheroids and verify transfer efficiency via the imaging system described in step 4.</li>
</ol>
7. Metabolic assay
<ol>
	<li>Sample degassing
	<ol>
		<li>Place the drug-treated spheroid assay plate into a preequilibrated 37 &#176;C hydration chamber devoid of CO2. 
		NOTE: Continuous degassing was performed for 1 h with strict environmental control to ensure metabolic measurement accuracy.</li>
	</ol>
	</li>
	<li>Reagent preparation and drug administration
	<ol>
		<li>Parallely prepare the reagent and load the drug during the 1-h degassing period. 
		NOTE: The primary objective of this experiment is to assess mitochondrial stress; all procedures must be meticulously aligned with this goal. Specific protocols must be followed for distinct experimental types to guarantee data accuracy and reliability.</li>
		<li>Drug preparation: Use the following compounds: 
		Oligomycin (mitochondrial complex V inhibitor) 
		Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP, uncoupler) 
		A mixture of rotenone (a complex I inhibitor) and antimycin A (a complex III inhibitor) 
		&#8203;NOTE: Drugs were obtained from the Mitochondrial Stress Test Kit used in this study. Some compounds are biohazardous; strict biosafety protocols (personal protective equipment and emergency preparedness) must be used.</li>
		<li>Drug formulation
		<ol>
			<li>Prepare the stock solutions of the powdered drugs as shown in Table 1.</li>
			<li>Dilute the stock solutions to the working concentrations specified in Table 2. 
			NOTE: The solutions are vortexed or agitated thoroughly to ensure homogeneity across concentration gradients.</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Loading compounds into detection probe cartridges 
	NOTE: Detection probe cartridge is a disposable cartridge containing biosensor probes for real-time measurement of oxygen and pH.
	<ol>
		<li>Probe cartridge activation (must precede compound loading): 
		NOTE: Ensure sensor activation by completing these steps at least 12 h before use:
		<ol>
			<li>Add 200 &#181;L of the calibrant solution to each well of the hydration plate.</li>
			<li>Position the detection probe cartridge carefully onto the hydration plate, ensuring complete immersion of all the probes in the calibrant solution.</li>
			<li>Incubate the assembled unit in a 37 &#176;C CO2-free incubator for 12-24 h to activate the sensors. 
			NOTE: Incomplete immersion or insufficient hydration causes measurement drift (&#177;15% OCR error).</li>
		</ol>
		</li>
		<li>Use multichannel or electronic pipettes to deliver precise volumes into wells, avoiding residual droplets at well edges. 
		NOTE: As acute drug stimulation is not needed, follow standard loading sequences.</li>
		<li>Place the probe plate on a stable surface after loading to prevent disturbances during transport. 
		NOTE: Loading accuracy significantly impacts the results.</li>
	</ol>
	</li>
	<li>Software configuration
	<ol>
		<li>Launch software and select the mitochondrial stress test assay protocol.</li>
		<li>Assign groups according to the predefined experimental grouping.</li>
		<li>Set the file name and click Start Run.</li>
	</ol>
	</li>
	<li>Calibration of detection probe cartridges.
	<ol>
		<li>Gently insert the loaded probe plate into the instrument slot per system prompt.</li>
		<li>Initiate calibration (15-20 min). Maintain stable conditions; avoid vibrations.</li>
		<li>Remove the hydration plate promptly post-calibration (following the on-screen instructions). 
		NOTE: Remove the plate lid prior to calibration.</li>
	</ol>
	</li>
	<li>Metabolic profiling of 3D spheroids
	<ol>
		<li>Transfer the degassed 3D spheroid assay plate to the instrument measurement slot. Ensure precise alignment with the probe array by confirming the following: (i) Plate corner match slot guides; (ii) Well A1 aligns with the indexed position; (iii) No visible gap between the plate and instrument surface</li>
		<li>Click Start to initiate mitochondrial stress assays (duration: ~1.5 h). Monitor instrument parameters throughout. 
		NOTE: Remove 3D spheroid assay plate lids before measurement.</li>
	</ol>
	</li>
	<li>Data analysis
	<ol>
		<li>Imaging analysis
		<ol>
			<li>Transfer 3D spheroid assay plates to a high-content imaging system. 
			NOTE: Images were acquired as described in step 4. Imaging revealed that the majority of the spheroids remained intact, whereas a minority sustained damage during the transfer process, as shown in Figure 3.</li>
			<li>Analyze the morphological data (e.g., area, length, width) of the cell spheroids via Harmony software version 5.2, following steps 7.7.1.3-7.7.1.7.</li>
			<li>Apply the Texture Region module coarsely to separate 3D spheroids from the background by dividing the image content into three clusters on the basis of the texture features of objects in the images.</li>
			<li>Apply the Find Image Region module to refine the separation of pre-isolated 3D spheroids via volume-based size characteristics to remove impurities and retain intact spheroids.</li>
			<li>Measure the morphological parameters of the 3D spheroids via the Morphology Properties module.</li>
			<li>Apply the Select Population module to ultimately filter out genuine 3D cell spheroids.</li>
			<li>Export the morphological data results, as shown in Table 3.</li>
		</ol>
		</li>
		<li>Data processing 
		NOTE: Normalize the cell data via parameters from the imaging outputs to minimize experimental artifacts.
		<ol>
			<li>Open the raw metabolic data via the analysis software.</li>
			<li>Select the Normalization Option to access the normalization mode editing interface.</li>
			<li>Input the cross-sectional area of spheroids contained in each corresponding well of the assay plate in the Normalization Values field.</li>
			<li>Set the scale factor parameter to 1,000,000.</li>
			<li>Click the Apply button to finalize the normalization process. The final results are shown in Figure 4.</li>
		</ol>
		</li>
	</ol>
	</li>
</ol>
8. Waste disposal
<ol>
	<li>Dispose of all experimental waste (media, reagents, consumables, and cell suspensions) according to biohazard and laboratory waste management protocols. Autoclave or chemically disinfect the bioactive waste before disposal to prevent environmental contamination.</li>
</ol>

<ol><li>Wu, W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Glioblastoma+multiforme+%28GBM%29%3A+An+overview+of+current+therapies+and+mechanisms+of+resistance%5BTitle%5D)+AND+%22Pharmacol+Res%22%5BJournal%5D)">Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.</a> Pharmacol Res. 171, 105780(2021).</li>
<li>Crowley, A. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((85th+annual+report+on+medical+education+in+the+United+States.+Executive+summary%5BTitle%5D)+AND+%22Jama%22%5BJournal%5D)">85th annual report on medical education in the United States. Executive summary.</a> Jama. 254 (12), 1553-1554 (1985).</li>
<li>Zhang, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Nutritionally+physiological+cell+culture+medium+and+3D+culture+influence+breast+tumor+proteomics+and+anticancer+drug+effectiveness%5BTitle%5D)+AND+%22Pharmacol+Res%22%5BJournal%5D)">Nutritionally physiological cell culture medium and 3D culture influence breast tumor proteomics and anticancer drug effectiveness.</a> Pharmacol Res. 210, 107519(2024).</li>
<li>Edmondson, R., Broglie, J. J., Adcock, A. F., Yang, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Three-dimensional+cell+culture+systems+and+their+applications+in+drug+discovery+and+cell-based+biosensors%5BTitle%5D)+AND+%22Assay+Drug+Dev+Technol%22%5BJournal%5D)">Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors.</a> Assay Drug Dev Technol. 12 (4), 207-218 (2014).</li>
<li>Bahl, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Growing+desmoplastic+three-dimensional+pancreatic+cancer+spheroids+from+coculture%5BTitle%5D)+AND+%22J+Vis+Exp%22%5BJournal%5D)">Growing desmoplastic three-dimensional pancreatic cancer spheroids from coculture.</a> J Vis Exp. 211, e66625(2024).</li>
<li>Faubert, B., Solmonson, A., Deberardinis, R. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Metabolic+reprogramming+and+cancer+progression%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Metabolic reprogramming and cancer progression.</a> Science. 368 (6487), eaaw5473(2020).</li>
<li>Baksh, S. C., Finley, L. W. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Metabolic+diversity+drives+cancer+cell+invasion%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Metabolic diversity drives cancer cell invasion.</a> Nature. 605 (7911), 627-628 (2022).</li>
<li>Yoshida, G. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Metabolic+reprogramming%3A+The+emerging+concept+and+associated+therapeutic+strategies%5BTitle%5D)+AND+%22J+Exp+Clin+Cancer+Res%22%5BJournal%5D)">Metabolic reprogramming: The emerging concept and associated therapeutic strategies.</a> J Exp Clin Cancer Res. 34, 111(2015).</li>
<li>Plitzko, B., Loesgen, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Measurement+of+oxygen+consumption+rate+%28OCR%29+and+extracellular+acidification+rate+%28ECAR%29+in+culture+cells+for+assessment+of+the+energy+metabolism%5BTitle%5D)+AND+%22Bio+Protoc%22%5BJournal%5D)">Measurement of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in culture cells for assessment of the energy metabolism.</a> Bio Protoc. 8 (10), e2850(2018).</li>
<li>Hong, X., Muñoz-Cánoves, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Measuring+oxygen+consumption+rate+%28OCR%29+and+extracellular+acidification+rate+%28ECAR%29+in+muscle+stem+cells+using+a+Seahorse+analyzer%3A+Applicability+for+aging+studies%5BTitle%5D)+AND+%22Methods+Mol+Biol%22%5BJournal%5D)">Measuring oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in muscle stem cells using a Seahorse analyzer: Applicability for aging studies.</a> Methods Mol Biol. 2640, 73-88 (2023).</li>
<li>Yoo, I., Ahn, I., Lee, J., Lee, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Extracellular+flux+assay+%28Seahorse+assay%29%3A+Diverse+applications+in+metabolic+research+across+biological+disciplines%5BTitle%5D)+AND+%22Mol+Cells%22%5BJournal%5D)">Extracellular flux assay (Seahorse assay): Diverse applications in metabolic research across biological disciplines.</a> Mol Cells. 47 (8), 100095(2024).</li>
<li>Kapałczyńska, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((2D+and+3D+cell+cultures+-+a+comparison+of+different+types+of+cancer+cell+cultures%5BTitle%5D)+AND+%22Arch+Med+Sci%22%5BJournal%5D)">2D and 3D cell cultures - a comparison of different types of cancer cell cultures.</a> Arch Med Sci. 14 (4), 910-919 (2018).</li>
<li>Rybkowska, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+metabolic+changes+between+monolayer+%282D%29+and+three-dimensional+%283D%29+culture+conditions+in+human+mesenchymal+stem%2Fstromal+cells+derived+from+adipose+tissue%5BTitle%5D)+AND+%22Cells%22%5BJournal%5D)">The metabolic changes between monolayer (2D) and three-dimensional (3D) culture conditions in human mesenchymal stem/stromal cells derived from adipose tissue.</a> Cells. 12 (1), 178(2023).</li>
<li>Białkowska, K., Komorowski, P., Bryszewska, M., Miłowska, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Spheroids+as+a+type+of+three-dimensional+cell+cultures-examples+of+methods+of+preparation+and+the+most+important+application%5BTitle%5D)+AND+%22Int+J+Mol+Sci%22%5BJournal%5D)">Spheroids as a type of three-dimensional cell cultures-examples of methods of preparation and the most important application.</a> Int J Mol Sci. 21 (17), 6225(2020).</li>
<li>Pinto, B., Henriques, A. C., Silva, P. M. A., Bousbaa, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Three-dimensional+spheroids+as+in+vitro+preclinical+models+for+cancer+research%5BTitle%5D)+AND+%22Pharmaceutics%22%5BJournal%5D)">Three-dimensional spheroids as in vitro preclinical models for cancer research.</a> Pharmaceutics. 12 (12), 1186(2020).</li>
<li>Juarez-Moreno, K., Chávez-García, D., Hirata, G., Vazquez-Duhalt, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Monolayer+%282D%29+or+spheroids+%283D%29+cell+cultures+for+nanotoxicological+studies%3F+Comparison+of+cytotoxicity+and+cell+internalization+of+nanoparticles%5BTitle%5D)+AND+%22Toxicol+In+Vitro%22%5BJournal%5D)">Monolayer (2D) or spheroids (3D) cell cultures for nanotoxicological studies? Comparison of cytotoxicity and cell internalization of nanoparticles.</a> Toxicol In Vitro. 85, 105461(2022).</li>
<li>Renner, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+fully+automated+high-throughput+workflow+for+3D-based+chemical+screening+in+human+midbrain+organoids%5BTitle%5D)+AND+%22Elife%22%5BJournal%5D)">A fully automated high-throughput workflow for 3D-based chemical screening in human midbrain organoids.</a> Elife. 9, e52904(2020).</li>
<li>Beaufort, I. N., et al. Author commentary on Ilse N. Beaufort et al. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aBeaufort%2C+IN+%22Endoscopy%22">Endoscopy</a>. 56 (5), v6(2024).</li>
<li>Liu, D., Chen, S., Win Naing, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+review+of+manufacturing+capabilities+of+cell+spheroid+generation+technologies+and+future+development%5BTitle%5D)+AND+%22Biotechnol+Bioeng%22%5BJournal%5D)">A review of manufacturing capabilities of cell spheroid generation technologies and future development.</a> Biotechnol Bioeng. 118 (2), 542-554 (2021).</li>
<li>Trettner, K. J., Hsieh, J., Xiao, W., Lee, J. S. H., Armani, A. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Nondestructive%2C+quantitative+viability+analysis+of+3D+tissue+cultures+using+machine+learning+image+segmentation%5BTitle%5D)+AND+%22APL+Bioeng%22%5BJournal%5D)">Nondestructive, quantitative viability analysis of 3D tissue cultures using machine learning image segmentation.</a> APL Bioeng. 8 (1), 016121(2024).</li>
<li>Dominijanni, A. J., Devarasetty, M., Forsythe, S. D., Votanopoulos, K. I., Soker, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cell+viability+assays+in+three-dimensional+hydrogels%3A+A+comparative+study+of+accuracy%5BTitle%5D)+AND+%22Tissue+Eng+Part+C+Methods%22%5BJournal%5D)">Cell viability assays in three-dimensional hydrogels: A comparative study of accuracy.</a> Tissue Eng Part C Methods. 27 (7), 401-410 (2021).</li>
</ol>

The authors have nothing to disclose.

The adaptation of extracellular flux analysis to 3D glioma models represents a critical methodological advancement in the study of tumor cell metabolism. While traditional 2D cultures have long served as the foundation for in vitro experimentation, they fail to capture the spatial architecture, cell-cell and cell-matrix interactions, and oxygen and nutrient gradients characteristic of in vivo tumors12. These features are especially relevant in gliomas, where metabolic reprogrammi...

Gliomas, a prevalent and aggressive form of brain tumor, pose significant clinical challenges because of their rapid progression, highly heterogeneous tumor microenvironment, and marked resistance to conventional therapies1. These complexities necessitate more physiologically relevant experimental models to improve the accuracy of therapeutic evaluations. Traditional two-dimensional (2D) cell culture systems fail to recapitulate the in vivo tumor architecture and cell-cell interactions2, often leading to misleading conclusions regarding drug efficacy and tumor biology3.
To address these limitations, three-dimensional (3D) tumor models have emerged as a superior alternative, offering enhanced biological relevance by mimicking the structural and functional characteristics of tumors in vivo4,5. Concurrently, metabolic reprogramming is increasingly recognized as a hallmark of glioma progression and treatment resistance6,7,8. Extracellular flux analysis has become a widely adopted technique for real-time measurement of key metabolic parameters, such as the extracellular acidification rate (ECAR, measuring proton efflux primarily from glycolytic lactate production) and the oxygen consumption rate (OCR, quantifying mitochondrial oxygen utilization in oxidative phosphorylation), providing critical insights into glycolytic and oxidative phosphorylation pathways9,10,11.
In this study, extracellular flux analysis was adapted to analyze 3D glioma spheroids, enabling the investigation of metabolic pathways in a context that closely resembles in vivo tumor conditions. U87 glioma cells were seeded at a density of 1,500 cells per well in transparent round-bottom ultra-low attachment 96-well plates and cultured for 5 days at 37 &#176;C with 5% CO2 to facilitate spheroid formation. High-content imaging was employed to confirm the spheroid morphology and assess the cell size. Prior to metabolic analysis, dense and circular 3D cell spheroids with a diameter of approximately 220 &#181;m were transferred to assay plates pre-coated with poly-L-lysine to ensure adhesion and measurement stability. Importantly, normalization of metabolic data on the basis of spheroid size was conducted via integrated high-content imaging, reducing variability and enhancing data reliability.
This integrated platform, combining 3D culture, extracellular flux analysis technology, and imaging-based normalization, enables a more accurate assessment of glioma metabolic responses to therapeutic interventions. This study provides a robust framework for studying the metabolic underpinnings of drug resistance and contributes to the development of more effective, clinically translatable treatment strategies for gliomas.

<table><tbody><tr><td>10 cm dish</td><td>Corning</td><td>430167</td><td></td></tr><tr><td>15 mL centrifuge tube</td><td>Corning</td><td>430791</td><td></td></tr><tr><td>50 mL centrifuge tube</td><td>Corning</td><td>430828</td><td></td></tr><tr><td>Calcein, AM</td><td>Invitrogen</td><td>C1430</td><td></td></tr><tr><td>Countess 3</td><td>Thermo Fisher</td><td></td><td>Automatic Cell Counter</td></tr><tr><td>Fetal Bovine Serum</td><td>Gibco</td><td>A5669701</td><td></td></tr><tr><td>Harmony 5.2</td><td>PerkinElmer</td><td></td><td>Imaging software</td></tr><tr><td>Hoechst 33342</td><td>Solarbio</td><td>C0031</td><td></td></tr><tr><td>MEM EBSS Medium</td><td>HyClone</td><td>SH30024.01</td><td></td></tr><tr><td>Operetta CLS</td><td>PerkinElmer</td><td></td><td>High-content imaging analysis system</td></tr><tr><td>PBS</td><td>HyClone</td><td>SH30256.01</td><td></td></tr><tr><td>Poly-D Lysine hydrobromide</td><td>Sigma&amp;nbsp;</td><td>P7280</td><td></td></tr><tr><td>Round-bottom ultra-low attachment 96-well plates</td><td>Corning</td><td>4515</td><td></td></tr><tr><td>Seahorse Wave Desktop software</td><td>Agilent</td><td></td><td></td></tr><tr><td>Seahorse XFe96</td><td>Agilent</td><td></td><td>Extracorporeal metabolic testing machine</td></tr><tr><td>Sorvall ST8R</td><td>Thermo Fisher</td><td></td><td>Centrifuge</td></tr><tr><td>TRYPSIN 0.25% EDTA</td><td>Gibco</td><td>25200072</td><td></td></tr><tr><td>U87MG cell line&amp;nbsp;</td><td>National Infrastructure of Cell Resource</td><td></td><td></td></tr><tr><td>XF 1.0 M Glucose Solution, 50 mL</td><td>Agilent</td><td>103577-100</td><td></td></tr><tr><td>XF 100 mM Pyruvate Solution, 50 mL</td><td>Agilent</td><td>103578-100</td><td></td></tr><tr><td>XF 200 mM Glutamine Solution, 50 mL</td><td>Agilent</td><td>103579-100</td><td></td></tr><tr><td>XF Calibrant Solution 500 mL&amp;nbsp;</td><td>Agilent</td><td>100840-000</td><td></td></tr><tr><td>XF Cell Mito Stress Test Kit</td><td>Agilent</td><td>103015-100</td><td></td></tr><tr><td>XF DMEM Medium, pH 7.4, 500 mL</td><td>Agilent</td><td>103575-100</td><td></td></tr><tr><td>XFe96/XF Pro Fluxpak-Detection Probe Array</td><td>Agilent</td><td>103792-100</td><td></td></tr><tr><td>XFe96/XF Pro Fluxpak-Metabolic Assay Plates</td><td>Agilent</td><td>103792-100</td><td></td></tr></tbody></table>

advancements in the metabolic profiling of three-dimensional brain tumor spheroids for drug screening

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Brain tumors, especially gliomas, are challenging to treat because of their aggressive nature, complex tumor microenvironment, and resistance to conventional therapies. Traditional two-dimensional (2D) cell cultures often fail to replicate the true tumor environment, leading to inaccurate predictions of drug efficacy. Extracellular flux analysis technology, typically used for real-time metabolic analysis in 2D cultures, measures key metabolic parameters, such as the extracellular acidification rate (ECAR) and oxygen consumption rate (OCR), providing insights into cellular metabolism. The use of 3D models represents a significant advancement, as they more accurately mimic the in vivo tumor environment. The extracellular flux analyzer was adapted to three-dimensional (3D) glioma cell models, enabling the analysis of critical metabolic pathways, including glycolysis and oxidative phosphorylation, in a more physiologically relevant context.
U87 cells were seeded at appropriate densities in a 96-well low-attachment plate and cultured for 5 days. On day 5, 3D spheroid formation was observed via high-content imaging. The successfully formed spheroids were then transferred to a metabolic assay plate coated with poly-L-lysine for metabolic analysis. To improve the accuracy of these measurements, high-content imaging systems assess 3D cell size, allowing for precise normalization of extracellular flux data and minimizing metabolic variations due to differences in cell size. This integrated approach provides a more reliable analysis of glioma cell metabolic responses to drug treatments, revealing potential mechanisms of drug resistance. Ultimately, this methodology offers valuable insights into the metabolic dynamics of gliomas and supports the development of novel, clinically relevant therapeutic strategies.

The three most critical steps in the energy metabolism detection process of 3D cell spheroids are the culture of 3D cell spheroids, the spheroid transfer process, and the imaging and quantification of spheroids after detection (Figure 1). Additionally, observing the state of the cell spheroids is highly important. When the experiments were conducted according to the abovementioned experimental procedures, spheroids were detected on the 5th day (Figure 2</stron...

Here, we establish a metabolic profiling platform integrating three-dimensional (3D) glioma spheroids and imaging-based normalization via extracellular flux analysis. This approach enables more accurate assessment of tumor metabolic responses to drug treatments and provides insights into potential mechanisms of resistance.

Brain tumors, especially gliomas, are challenging to treat because of their aggressive nature, complex tumor microenvironment, and resistance to ...

The research aims to optimize 3D cell cell root formation for studying energy metabolism using Seahorse technology, focusing on cell behavioral metabolic activity and drug responses in our clinically-relevant model. This findings will enhance drug casting models by providing a more accurate representation of brain tumors, improving therapy evaluation, and metabolic analysis for better treatment strategies. The results paved the way for investigating how energy metabolism alters in 3D spheroid models, how drugs exit effects on metabolic pathways, and the mechanisms by which metabolic changes contribute to the development of tumor resistance to therapy.After resuspending the collected U87 cells in DMEM, preheat the unused medium to 37 degrees Celsius. Maintain the cell suspensions at room temperature for 30 minutes. Based on the initial cell count, dilute the cell suspension with DMEM containing 10%FBS to a final volume of 20 milliliters, ensuring approximately 200, 000 cells.Mix the final cell suspension thoroughly by repeated inversion. Slowly add 200 microliters of the suspension along the edge of each well in a transparent round bottom ultra-low attachment 96-well plate, then seal the plate tightly with Parafilm to prevent leakage during centrifugation. Place the sealed plate in the centrifuge and run at 200 G for two minutes to pellet the cells at the bottom of each well.Remove the plate from the centrifuge. Carefully remove the Parafilm, and place the plate in a 37 degrees Celsius incubator with 5%carbon dioxide. To prepare a coating solution, dissolve five milligrams of Poly-D-Lysine in 50 milliliters of sterile water, and mix the solution thoroughly, until completely dissolved.Add 30 microliters of the coating solution to each well of the metabolic assay plate. Ensure the absence of bubbles by gently shaking the plate or aspirating the excess solution. Incubate the plate with the cover on for 20 minutes at room temperature, then aspirate the coating solution, and wash the wells twice with 200 microliters of sterile water.Air dry the plate for at least 30 minutes, then heat the plate at 37 degrees Celsius without carbon dioxide for 30 minutes to stabilize the coating. Afterward, add 175 microliters of preheated medium to each well. Keep the plate at 37 degrees Celsius in a carbon dioxide-free incubator, until it is ready for cell spheroid transfer.Transfer the spheroid plates to a high-content imaging system after five days of culture. To configure the imaging parameters, set the temperature to 37 degrees Celsius and the carbon dioxide level to 5%Adjust the plate type, channels, and focus range on the system settings. Next, acquire spheroid images using a confocal microscope with 10 times objectives and the imaging software, then identify wells containing intact spheroids, and record their positions for transfer.Assign the intact spheroids to two groups, a control group with six replicate wells and a treatment group with six replicate wells for fenofibrate treatment. Prepare the fenofibrate working solution in fresh prewarm medium at the optimal concentration. Carefully remove the spheroid containing low-attachment plate from the imaging system and place it on a sterile surface inside a biosafety cabinet.Position the Poly-D-Lysine-coated assay plate adjacent to it for transfer, then trim the tip of a 20 microliter pipette to allow gentle aspiration of the cell spheroids without causing damage. Using the trimmed pipette tip, gently aspirate each intact spheroid from the bottom of its well. Transfer each spheroid to the corresponding well of the coated plate, and allow it to settle for 20 seconds.Transfer the 3D spheroid assay plates to a high-content imaging system. To analyze the morphological data, apply the texture region module to coarsely separate 3D spheroids from the background by dividing the image content into three clusters based on texture features. Apply the find image region module to refine the separation of preisolated 3D spheroids by using volume-based size characteristics, ensuring impurities are removed and intact spheroids are retained.Measure the morphological parameters of the 3D spheroids using the morphology properties module. Apply the select population module to filter and retain only genuine 3D cell spheroids, then export the morphological data results. Spheroids were visibly formed by the fifth day of culture, maintaining a uniform spherical morphology across all observed samples.A disintegrated spheroid with visibly disrupted structural integrity was also observed on day five. Post-transfer analysis revealed that both control and fenofibrate-treated 3D spheroids remained intact in most cases, but some fenofibrate-treated spheroids were disintegrated. Oxygen consumption rate was significantly reduced in fenofibrate-treated spheroids across all time points compared to the control group.

advancements-metabolic-profiling-three-dimensional-brain-tumor

Research

JoVE Journal

Cancer Research

Invasion of surrounding normal tissues is a defining characteristic of malignant tumors. We provide here a simple, semi-automated micro-plate assay of invasion into a natural 3D biomatrix that has been exemplified with a number of models of advanced human cancers.

Three-Dimensional (3D) Tumor Spheroid Invasion Assay

Patient-derived xenografts of glioblastoma multiforme can be miniaturized into living microtumors using 3D human biogel culture system. This in vivo-like 3D tumor assay is suitable for drug response testing and molecular profiling, including kinomic analysis.

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Here, a method is described for the preparation of 3-dimensional (3D) spheroid co-culture of pancreatic cancer cells and fibroblasts, followed by measurement of metabolic functions using an extracellular flux analyzer.

Preparation and Metabolic Assay of 3-dimensional Spheroid Co-cultures of Pancreatic Cancer Cells and Fibroblasts

Across a wide variety of disease indications, more physiologically relevant models are being developed and implemented into drug discovery programs. The new model system described here demonstrates how three-dimensional tumor spheroids can be cultured and screened in a high-throughput 1536-well plate-based system to search for new oncology drugs.

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Optical coherence tomography (OCT), a three-dimensional imaging technology, was used to monitor and characterize the growth kinetics of multicellular tumor spheroids. Precise volumetric quantification of tumor spheroids using a voxel counting approach, and label-free dead tissue detection in the spheroids based on intrinsic optical attenuation contrast, were demonstrated.

Longitudinal Morphological and Physiological Monitoring of Three-dimensional Tumor Spheroids Using Optical Coherence Tomography

The effects of migrastatic inhibitors on glioma cancer cell migration in three-dimensional (3D) invasion assays using a histone deacetylase (HDAC) inhibitor are characterized by high-resolution confocal microscopy.

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy

Here, we describe an easy-to-use invasion assay for glioblastoma. This assay is suitable for glioblastoma stem-like cells. A Fiji macro for easy quantification of invasion, migration, and proliferation is also described.

A 3D Spheroid Model for Glioblastoma

These protocols will help users probe mitochondrial energy metabolism in 3D cancer cell-line-derived spheroids using Seahorse extracellular flux analysis.

Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis

The present protocol describes generating 3D tumor culture models from primary cancer cells and evaluating their sensitivity to drugs using cell-viability assays and microscopic examinations.

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

This article demonstrates a standardized method for constructing three-dimensional tumor spheroids. A strategy for spheroid observation and image-based deep-learning analysis using an automated imaging system is also described.

Generation of 3D Tumor Spheroids for Drug Evaluation Studies

Learn metabolic profiling of 3D glioma spheroids using Seahorse technology for drug screening. This method reveals tumor energy metabolism and resistance mechanisms to improve cancer therapy evaluation.

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Explore More Videos